As epidemiological studies also showed that the expression of anti-apoptotic BCL-2 can be higher than the expression of BCL-xL and MCL-1 in skin cancer cells (D’Aguanno and del Bufalo 2020), BH3 mimetic substances are in the focus of research and clinical trials (Kehr and Vogler 2021). This evidence concerns the gene BCL2 and skin neoplasm.